Alexion’s groundbreaking shift to biomethane paves the way for pharma’s decarbonisation in Ireland

Alexion, AstraZeneca Rare Disease, has announced a pioneering commitment to sustainability by transitioning to 100% renewable energy for its operations in Ireland, marking an important milestone in industrial decarbonisation within the pharmaceutical sector. The company will meet all heating needs at its Dublin and Athlone sites through biomethane, sourced under a landmark 15-year agreement with Carbon AMS, a prominent biomethane producer. This initiative represents the first instance in Ireland where a pharmaceutical firm adopts biomethane fully for its research, development, and manufacturing heat requirements.

The biomethane will be supplied from a purpose-built anaerobic digestion facility being developed in Duleek, County Meath, some 30km from Dublin and 120km from Athlone. The plant, expected to be commissioned in 2026 with initial deliveries in the fourth quarter, will use grass silage feedstock secured through long-term contracts with local farmers. This creates a dual benefit: generating renewable gas for industrial use while providing farmers with sustainable new income streams, thus supporting Ireland’s agricultural economy and circular bioeconomy. The project is backed by a €100 million strategic partnership involving SDCL and Carbon AMS, underscoring significant private-sector investment in renewable gas infrastructure.

The Duleek facility is planned to deliver at least 32 GWh of biomethane annually to Alexion’s Irish sites, equivalent to around 6.3% of AstraZeneca’s global natural gas consumption. This shift is projected to cut about 5,800 tonnes of CO2 equivalent emissions each year, contributing measurably to the company’s Ambition Zero Carbon programme , AstraZeneca’s flagship global decarbonisation strategy. Beyond energy provision, the biomethane production process will yield nutrient-rich by-products that can be returned to farmland, enhancing soil health, stimulating grass growth, and reducing reliance on synthetic fertilisers. This integration exemplifies the company’s commitment to sustainable agricultural practices alongside industrial decarbonisation.

Government officials have welcomed the initiative as a demonstrable example of advancing national climate objectives. Minister for Transport and Minister for Climate, Energy and the Environment Darragh O’Brien TD called the project “a significant contribution to the National Biomethane Strategy,” highlighting how private sector partnerships like this can drive tangible environmental benefits and promote energy independence for Ireland.

From Alexion’s perspective, senior leaders have emphasised the scale and innovation of the transition. Shane Doyle, Senior Vice President of Global Operations and Sustainability, described the partnership as “a pivotal moment in our sustainability journey” that positions the company as a renewable energy pioneer within the pharmaceutical industry. Bryan Mulchinock, Global Head of Environmental Health and Safety, acknowledged the complexity of implementing biomethane at this scale but noted the strategic alignment with Ireland’s growing biomethane sector and renewable energy ambitions.

Richard Kennedy, CEO of Carbon AMS, also highlighted the broader implications for Ireland’s energy landscape, describing the agreement as “a game-changer” for indigenous renewable gas production, local agricultural support, and energy resilience.

This biomethane project builds on AstraZeneca’s broader sustainability investments globally, with previous upgrades at sites in the US, UK, and China involving clean heat technologies for research and manufacturing environments. Moreover, AstraZeneca is investing significantly in its Irish operations, including a €65 million programme at Alexion’s Blanchardstown and Athlone facilities to expand biologics manufacturing capabilities, further underlining the company’s long-term industrial presence in Ireland.

The move to biomethane aligns with wider industry efforts to decarbonise energy-intensive processes in pharmaceutical production, contributing to the sector’s sustainability credentials. It is also a hopeful signal for stakeholders in industrial decarbonisation, demonstrating how renewable gas can integrate effectively into existing infrastructure while supporting local economies and national climate goals.

Overall, Alexion’s biomethane transition illustrates the confluence of corporate environmental responsibility, innovative renewable energy solutions, and strategic partnerships driving forward the low-carbon transformation of industrial operations in Ireland and beyond.